Navigation Links
Transposagen Issued Two Key U.S. Patents

LEXINGTON, Ky., Nov. 1, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today the issuing of Patent No. 8,399,643 entitled, "Nucleic Acids Encoding Hyperactive PiggyBac Transposases" on March 19th and Patent No. 8,558,055 entitled, "A Genetically Modified Rat Comprising a Cytokine Gene Disruption and Exhibiting a Greater Susceptibility to a Cytokine-Mediated Autoimmune and/or Inflammatory Disease" on October 15th. The patents have terms extending through 2030.


The piggyBacTM DNA transposon is the most efficient and safe technology for delivering DNA stably into the genome of animals and is being used in biomedical, agricultural and human therapeutic applications. Transposagen tested over 2 million variations of the piggyBacTM transposase enzyme and discovered versions of the enzyme that are more than 10 times more active than the version found in nature. The piggyBacTM technology is also a critical component of Footprint-FreeTM Gene Editing, one of the only commercially available methods to edit as little as a single nucleotide in the genome of nearly any organism. "The new 'super piggyBacTM vectors and PB-GoldTM kit, will allow researchers to perform stable transfection for the same cost and on the same timeline as transient transfection." said Jack Crawford, M.Sc., Transposagen's Director of Sales and Marketing.

The more recent patent covers all genetically modified rats that model lymphocyte proliferation, autoimmune disease or inflammatory disease, including all genetically modified rats with dysfunction in macrophages, immunoglobulin, T-cells, B-cells and/or NK-cells. The patent further covers any assay that screens for potentially useful therapeutic compounds using cells derived from the genetically modified rats. "This patent, and other imminent patents that cover genetically modified rat models of cancer and other diseases, cements Transposagen's position as a premier provider of custom genetically modified rodents," said Eric Ostertag, M.D., Ph.D., President & CEO of Transposagen. "We are proud to be the sole provider of valuable research reagents, such as the hyperactive piggyBacTM transposase and rat models of inflammatory disease, to the research community."

Please see piggyBacTM for more information, as well as Disease Model Partnering Strategy for opportunities in rodent model creation.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc. is a worldwide leader in technologies and services for genetic modification. Transposagen specializes in gene editing tools and custom cell line and animal model creation. To learn more, please visit:

Media Contact: Jack Crawford, Transposagen Biopharmaceuticals, (315) 351-9115,

News distributed by PR Newswire iReach:

SOURCE Transposagen Biopharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Transposagen Receives Over $4.3M in Grants and Investment
2. Enbrel® (etanercept) Patent Issued
3. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
4. 12th U.S. Patent Issued To Dyadic International
5. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
6. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
7. Stemedica Issued U.S. Patent For Ectodermal Stem Cells
8. PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
9. PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
10. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
11. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):